Efficacy and Safety of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 Chronic Kidney Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Biopsy-proven IgA nephropathy;
• Proteinuria ≥1.0g/day while receiving maximum tolerated dose of RAS blockade;
• Estimated glomerular filtration rate 15-60 ml/min/1.73/m2.
Locations
Other Locations
China
AFMMU
RECRUITING
Xi'an
Time Frame
Start Date: 2024-02-01
Estimated Completion Date: 2028-08
Participants
Target number of participants: 208
Treatments
Active_comparator: CS
low-dose corticosteroids monotherapy
Active_comparator: CS+CTX
low-dose corticosteroids combined with cyclophosphamide
Related Therapeutic Areas
Sponsors
Leads: Air Force Military Medical University, China